Scientific News: Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This ..

Choose a language:

Science Daily Reports

Details: Written by Bing News Search Results; Category: Science Daily Reports; Published: 11 August 2026; Created: 11 August 2026; Last Updated: 11 August 2026

Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year ...
Original Image Link
Source:www.fool.com

Posted: 2026-08-10 11:54:00

Get Full News Story On Bing Science News Network

More News From This Category
Scientific News: Boston Scientific unveils new restructuring plan, expects job cuts
Tue, 11 Aug 2026 04:07:30 +0000

July 27 (Reuters) - Boston Scientific's board has approved a new company-wide restructuring plan aimed at cutting costs and to better position the company for future growth, the medical device maker ...
Original Image Link
Source:www.msn.com

Scientific News: Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Mon, 10 Aug 2026 19:07:29 +0000

Scientific News: Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Mon, 10 Aug 2026 19:07:29 +0000

Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.
Original Image Link
Source:www.fool.com

Scientific News: Core Scientific: A Growth Story Behind Colocation Moat
Mon, 10 Aug 2026 16:07:21 +0000

Core Scientific is rated Buy: booming AI colocation revenue, long-term AMD/CoreWeave contracts, strong outlook, and 93% upside potential. Click to read more.
Original Image Link
Source:seekingalpha.com

Related Bing News Results
Climate scientist who “proved” humanity is warming Earth says government report got it wrong
Wed, 01 Jul 2026 17:00:00 GMT
A pioneering climate scientist is challenging a U.S. government report that cited his research while reaching what he says is the exact opposite conclusion. Benjamin Santer and his colleagues say ...